Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 6/20 | 0.37 |
| ▸ | JAK1 | P23458 | 6/20 | 0.37 |
| ▸ | TYK2 | P29597 | 6/20 | 0.37 |
| ▸ | JAK3 | P52333 | 6/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12670976 | 0.89 | HCAR3 (0.40) | NPC1KMT2APTGER4THRBKDM4E | |
| SCHEMBL15778085 | 0.89 | NPC1 (0.39) | NPC1KMT2ATHRBKDM4E | |
| SCHEMBL1418432 | 0.87 | KDM4E (0.42) | NPC1KMT2APTGER4THRBKDM4E | |
| SCHEMBL1417918 | 0.85 | THRB (0.43) | NPC1KMT2ATHRBKDM4E | |
| SCHEMBL3376854 | 0.82 | KDM4E (0.48) | NPC1KMT2AKDM4EGLA | |
| SCHEMBL15778043 | 0.81 | MAPT (0.41) | NPC1KMT2A | |
| SCHEMBL15785617 | 0.81 | MAPT (0.41) | NPC1KMT2A | |
| SCHEMBL15778045 | 0.80 | NPC1 (0.34) | NPC1THRB | |
| SCHEMBL2317816 | 0.80 | DGAT1 (0.42) | NPC1PTGER4 | |
| SCHEMBL23448580 | 0.79 | NPC1 (0.43) | NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4053108-B1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-20260055063-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| US-12503444-B2 | Compound containing benzene ring and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| CN-114845996-B | Benzene ring-containing compound and application thereof | 武汉朗来科技发展有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230183182-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-4053108-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055063-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | CNR2, RYR2, CNR1 | NPC1 706/4885KMT2A 4122/4885JAK2 317/4885 |
| US-12503444-B2 | Compound containing benzene ring and application thereof | P2RX4, P2RX7, P2RX2 | NPC1 1217/4885KMT2A 4083/4885JAK2 210/4885 |
| US-20230183182-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | P2RX4, P2RX7, P2RX2 | NPC1 1217/4885KMT2A 4083/4885JAK2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.